A Robust RP-HPLC Method for Simultaneous Estimation of Paracetamol and Nefopam in Human Plasma: Design of Experiments Approach

Why It Matters

The method delivers a fast, reliable tool for measuring two analgesics together, streamlining clinical studies and reducing analytical costs in the pharmaceutical industry.

Key Takeaways

• Runs under 8 minutes per sample
• QbD approach optimizes resolution and reproducibility
• Linear range covers therapeutic plasma concentrations
• Validated for stability, matrix effects, and precision

Pulse Analysis

The pharmaceutical landscape increasingly relies on high‑throughput bioanalysis to support drug development and post‑marketing surveillance. By leveraging a Quality by Design (QbD) strategy, the new RP‑HPLC method systematically identifies critical method parameters—such as mobile‑phase composition, flow rate, and detection wavelength—ensuring consistent performance across batches. This disciplined approach not only shortens method‑development timelines but also builds regulatory confidence, as QbD documentation aligns with FDA and EMA expectations for method robustness.

Simultaneous quantification of paracetamol and nefopam addresses a practical gap in analgesic research. Both agents are frequently co‑prescribed, yet traditional assays require separate runs, inflating laboratory workload and sample consumption. The validated method delivers precise, accurate results across clinically relevant concentration ranges (10‑50 µg/mL for paracetamol, 1‑5 µg/mL for nefopam) with %RSD well within bioanalytical guidelines. Its rapid 0.7 mL/min flow and 255 nm detection enable high‑throughput processing, making it ideal for large pharmacokinetic studies and bioequivalence trials where turnaround time is critical.

Beyond drug development, the assay supports therapeutic drug monitoring (TDM) in real‑world settings. Accurate plasma levels of paracetamol and nefopam can guide dosing adjustments, improve patient safety, and reduce adverse events associated with over‑ or under‑exposure. The method’s demonstrated stability under varied storage conditions further ensures reliable results from routine clinical laboratories. As healthcare systems prioritize cost‑effective, evidence‑based pain management, this robust analytical tool offers a scalable solution that bridges research and bedside care.